Results 181 to 190 of about 106,865 (295)

Live-Cell Raman Imaging Elucidates Intracellular Distribution of Macrocyclic Peptides Designed as HIV Protease Inhibitors. [PDF]

Chem Biomed Imaging
Nawa Y, Miyano T, Bando K, Mitsuki S, Hayashi K, Tanaka Y, Ueda H, Fujita S, Fujita K.   +8 more
europepmc   +1 more source

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero, Niall Prendiville, Tatiana Cazorla, Maria Baena‐Nuevo, Röhm Sandra, Emilio Camafeita, Stefan Knapp, Patricia Alfonso   +7 more
wiley   +1 more source

Asymmetric Synthesis of the HIV Protease Inhibitor TMC-126, a PMX Antimalarial Protease Inhibitor, and a Putative COVID-19 Inhibitor Using a Highly Stereoselective Glycolate Aldol Addition Reaction Pathway. [PDF]

ACS Omega
Affram KA, Carter A, Breede A, Kimsey A, Hemeson G, Semakieh B, Martinez M, Ayim E, Odeh J, Hitchcock SR.   +9 more
europepmc   +1 more source

Hiv-1 Protease Molecular Dynamics of a Wild-Type and of the V82f/I84v Mutant: Possible Contributions to Drug Resistance and a Potential New Target Site for Drugs

, 2009
The protease from type I human immunodeficiency virus (HIV-1 ) is a critical drug target against which many therapeutically useful inhibitors have been developed; however, the set of viral strains in the population has been shifting to become more drug ...
ALEXANDER L. PERRYMAN;LIN, JUNG-HSIN;J. ANDREW MCCAMMON, 林榮信   +1 more
core  

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

International Journal of Cancer, Volume 158, Issue 12, Page 3268-3278, 15 June 2026.
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt, Sami Kilpinen, Johanna Arola, Benjamin Z. Sundqvist, Tom Böhling, Leif C. Andersson, Harri Sihto   +6 more
wiley   +1 more source

Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2. [PDF]

J Med Chem
Haymer DH, Duncan RA, Rodriguez AL, Han A, Lindsay RJ, Wijesiri NK, Thompson Gray A, Krishnan S, Qi A, Brown BP, Boutaud O, Engers DW, Jones CK, Niswender CM, Lindsley CW, Bender AM.   +15 more
europepmc   +1 more source

Human immunodeficiency virus rebound after suppression to < 400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression

, 2002
This study evaluated 1433 human immunodeficiency virus (HIV)-infected patients starting highly active antiretroviral therapy (HAART), 409 (28%) of whom had prior nucleoside experience and achieved an HIV load of
Klauke, S, Royal Free Ctr HIV Med Goethe Univ, Phillips, AN, Bickel, M, Johnson, MA, Doerr, HW, Youle, MS, Loveday, C, Miller, V, Lampe, F, Staszewski, S, Sabin, CA   +11 more
core  

HIV‐1 establishes immediate latency in T cells expressing the viral Nef protein

FEBS Open Bio, Volume 16, Issue 6, Page 1132-1141, June 2026.
Nef is a viral protein often omitted from HIV‐1 reporter viruses. Consequently, its role in viral latency is unclear. We developed three novel dual reporter HIV‐1 derivatives that express Nef and allow for detection of latent and productive infection. Using these reporters, we show that Nef does not affect the establishment of immediate viral latency ...
Cindy Lam, Ivan Sadowski
wiley   +1 more source

Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design. [PDF]

Molecules, 2021
Yu W, Wu X, Zhao Y, Chen C, Yang Z, Zhang X, Ren J, Wang Y, Wu C, Li C, Chen R, Wang X, Zheng W, Liao H, Yuan X.   +14 more
europepmc   +1 more source

Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers

Advanced Functional Materials, Volume 36, Issue 44, 1 June 2026.
A biodegradable carrier‐based peptide delivery system is a powerful treatment platform for diverse diseases, owing to its superior therapeutic efficacy and low toxicity. This review examines the conventional peptide‐loaded carrier fabrication process and its current limitations.
Wookyoung Jang, Ki Wan Bong
wiley   +1 more source